Open-Angle Glaucoma / Ocular Hypertension

About The Study:
Sponsored by Allergan, the purpose of this multi-center study, called ARTEMIS, is to investigate the safety and effectiveness of Bimatoprost SR.

All participants will be randomized to one of three study groups:

- **Group A**—Bimatoprost SR (low dose) in the primary eye and Timolol in the fellow eye
- **Group B**—Bimatoprost SR (high does) in the primary eye and Timolol in the fellow eye
- **Group C**—Timolol in both eyes

Participants participating in this study will make up to 25 scheduled study visits and 6 phone calls over a period of 22 months. Each visit will last anywhere from 2-5 hours.

Key Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of either OAG (primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in each eye and both eyes require IOP-lowering treatment
- IOP ≥ 22 and ≤ 32 mmHg
- BCVA of 20/50 or better in the study eye

Key Exclusion Criteria:
- History of previous laser trabeculoplasty
- History of traumatic cataract and/or angle recession
- History of peripheral iridotomy/iridectomy in the inferior 180° of the iris
- Any history of trabeculectomy or other types of glaucoma surgery
- History of moderate or worse (≥2+) bulbar conjunctival hyperemia due to prostaglandin, prostamide, or prostaglandin use

For Additional Information Or To Refer A Patient, Contact:
Principal Investigator: Bruce E. Prum, Jr., MD
Study Coordinators: Ashton Leone, MPH, CCRP at (434) 243-5737 or aml7q@virginia.edu
Tamika Mercer, COA at (434) 243-2852 or tmm2v@virginia.edu
Allison Weiderhold at (434) 243-2921 or alw5rm@virginia.edu